Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

conciliation from Reported Net Income Available to Common Shareholders and Reported Diluted Earnings Per Common Share to As Reconciled Amounts for Net Income

Available to Common Shareholders and Diluted Earnings per Common Share (unaudited)
(Amounts in Millions, except per share figures)

Three months ended December 31, 2006

Purchase Acquisition- Other

As Accounting Related Specified As

Reported Adjustments Items Items Reconciled

Net sales $2,650 $ - $ - $ - $2,650

Cost of sales 915 - - (45) 870

Selling, general

and administrative 1,250 - - - 1,250

Research and

development 631 - - (15) 616

Acquired in-process

research and

development - - - - -

Other income, net (46) - - - (46)

Special and

acquisition

related charges 12 - - (12) -

Equity income (403) - - - (403)

Income before

income taxes 291 - - 72 363

Income tax expense 87 - - - 87

Net income before

cumulative effect

of a change in

accounting principle $204 $ - $ - $72 $276

Cumulative effect of

a change in

accounting principle,

net of tax - - - - -

Net income $204 $ - $ - $72 $276

Preferred stock

dividends 22 - - -
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. (OTCQB: ... 400 million people worldwide are living with diabetes, with  ... by 2030.  The global market for diabetes treatments is ... 330,000 people worldwide died from pancreatic cancer.  Pancreatic cancer ... to cancer in the United States ...
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th ... will take place at the Congress Center ... is now available at http://www.abim.ch . ... organizations from all over the globe will ... latest products and developments on the world ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Eisai Corporation of North,America and its U.S. subsidiary, ... and Drug Administration (FDA) Advisory Committee on Anesthetic,and ... 3 in favor (with one,abstention) of approval of ... agent for sedation in adult patients,undergoing diagnostic or ...
... WALTHAM, Mass., May 7 Interleukin Genetics,Inc. (AMEX: ... conference call and,webcast on Wednesday, May 14, 2008 at ... financial results and provide an update on recent,corporate developments., ... or 719-325-4869,(international). The live webcast will be available on ...
... and Other ... to Nektar, SAN CARLOS, Calif., May 7 ... U.S. Patent and Trademark Office,has issued Patent No. 7,368,102, ... Inhalation Powder (TIP) and other,aminoglycoside antibiotics delivered via Nektar,s ...
Cached Biology Technology:FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation 2FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation 3Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results 2Nektar Receives Patent Covering Pulmonary Targeted Antibiotics 2Nektar Receives Patent Covering Pulmonary Targeted Antibiotics 3
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology , ... announced the availability of the VeriLook Surveillance ... 3.0 provides real-time biometric face identification using live ... surveillance cameras. The new version not only identifies ... people from objects while they are moving through ...
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
(Date:10/14/2014)... Scientists from The Scripps Research Institute (TSRI) have been ... (NIH) to lead an investigation of Lassa fever virus, ... The study aims to understand how Lassa fever virus ... survive the inflection. , "The ultimate goal is ... Lassa fever virus causes disease and develop new treatments ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... of Nepenthes gracilis pitchers acts like a ... directly into the fluid-filled pitcher, new research has found. ... the journal PLoS ONE . Pitcher plants ... enabling them to colonise nutrient-poor habitats where other plants ...
... cells in you as there are your own cells. ... inhabit your skin, mouth, gut, and other parts of your ... healthy. These communities are also thought to cause disease when ... is poorly understood. That could change. A National Institutes ...
... 2012 Scientists at The Scripps Research Institute have ... that inhibit the activity of human immunodeficiency virus (HIV), ... the compounds bind to a protein called "nucelocapsid," which ... "Most of the nucleocapsid-inhibiting compounds that have been identified ...
Cached Biology News:Pitcher plant uses rain drops to capture prey 2Berkeley Lab scientists help define the healthy human microbiome 2Berkeley Lab scientists help define the healthy human microbiome 3Berkeley Lab scientists help define the healthy human microbiome 4New drug-screening method yields long-sought anti-HIV compounds 2New drug-screening method yields long-sought anti-HIV compounds 3
...
...
Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Biology Products: